Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

American Journal of Psychiatry

Volumn 154, Issue 4, 1997, Pages 466-474

  Tollefson, Gary D ^a   Sanger, Todd M ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0031003781     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.4.466     Document Type: Article

References (41)

1. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M: Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52:341-351
2. Andreasen NC, Olsen S: Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39:789-794
3. Eaton WW, Thara R, Federman B, Melton B, Liang K: Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 1995; 52:127-134
4. Crow TJ: Molecular pathology of schizophrenia: more than one disease process? BMJ 1980; 280:66-68
5. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P: A longitudinal study of symptom dimensions in schizophrenia: prediction and patterns of change. Arch Gen Psychiatry 1995; 52:352-360
6. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827-832
7. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
9. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
10. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
11. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976
12. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
13. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
14. SAS/STAT User's Guide, version 6, 4th ed, vols 1, 2. Cary, NC, SAS Institute, 1990
15. Snedecor GW, Cochran WG: Statistical Methods, 7th ed. Ames, Iowa University Press, 1980
16. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1995; 245:45-49
17. Retherford RD, Kim Choe MK: Path analysis, in Statistical Models for Causal Analysis. New York, John Wiley & Sons, 1993, pp 93-99
18. Peralta V, Cuesta MJ: Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models. Am J Psychiatry 1995; 152:1450-1457
19. Andreasen NC, Grove WM: Evaluation of positive and negative symptoms in schizophrenia. Psychiatrie et Psychobiologie 1986; 1:108-121
20. Kirkpatrick B, Buchanan R, Breier A, Carpenter W: Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res 1993; 47:47-56
21. Goldberg SC: Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985; 11:453-456
22. Meltzer HY, Sommers AA, Luchins DJ: The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986; 6:329-338
23. Opler LA, Albert D, Ramirez PM: Psychopharmacologic treatment of negative schizophrenic symptoms. Compr Psychiatry 1994; 35:16-28
24. Tandon R, Goldman RS, Goodson J, Greden JF: Mutability and relationship between positive and negative symptoms during neuroleptic treatment. Biol Psychiatry 1990; 27:1323-1326
25. Tandon R, Ribeiro SCM, DeQuardo JR, Goodman RS, Goodson J, Greden JF: Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry 1993; 34:495-497
26. van Kammen DP, Hommer DW, Malas KL: Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? Neuropsychobiology 1978; 18:113-117
27. Kane J, Mayerhoff D: Do negative symptoms respond to pharmacologic treatment? Br J Psychiatry 1989; 55(suppl 7):115-118
28. Kirkpatrick B, Carpenter WT: Drug development and the deficit syndrome of schizophrenia. Biol Psychiatry 1995; 38:277-278
29. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
30. Honigfeld G, Patin J: Predictors of response to clozapine therapy, Psychopharmacology (Berl) 1989; 99:564-567
31. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M: Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27:341-347
32. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Boodstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
33. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary report. Psychopharmacology (Berl) 1989; 99(suppl):S68-S72
34. Meltzer HY: Clozapine: pattern of efficacy in treatment-resistant schizophrenia, in Novel Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press, 1992, pp 33-46
35. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15
36. Stockton ME, Rasmussen K: Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 1996; 124:50-56
37. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC: The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2:281-293
38. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16:1-7
39. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996; 124:148-153
40. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
41. Conley R, Gounaris C, Tamminga C: Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35:746-747